GlassScriptPhysician profile
Amit S Narayan
NPI 1053774141
$3,739.46
in general payments reported to CMS, 2019-2025
33 companies · $864 in 2025
The $864 reported for 2025 was more than what 94% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.03 · 2022: $176 · 2023: $1,071 · 2024: $1,613 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,540 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,539.82 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $624.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $428.07 | 2022-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $337.06 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $336.77 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $318.89 | 2022-2024 | |
| Noven Therapeutics, LLC | $297.57 | 2023-2025 | Xelstrym |
| Astrazeneca Pharmaceuticals LP | $262.30 | 2023-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $228.70 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Esperion Therapeutics, INC. | $192.80 | 2023-2025 | Nexletol |
| Exact Sciences Corporation | $124.09 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $55.92 | 2023-2024 | |
| Pfizer INC. | $52.93 | 2023-2025 | |
| Boston Scientific Corporation | $48.39 | 2025 | General - Pain Management, Bodyguardian |
| Philips North America LLC | $42.25 | 2024 | (Ck7) Extended Holter |
| Sanofi Pasteur INC. | $35.82 | 2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $30.21 | 2024 | Evoke |
| Linus Health, INC. | $28.34 | 2022-2024 | Core Cognitive Evaluation |
| Si-Bone, INC. | $26.53 | 2023 | |
| Baxter Healthcare | $24.48 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Azurity Pharmaceuticals, INC. | $21.07 | 2024 | Edarbyclor |
| Sanofi-Aventis U.S. LLC | $20.91 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.98 | 2022 | |
| Dexcom, INC. | $18.71 | 2025 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $18.64 | 2024 | Opsumit, Uptravi |
| Abbott Laboratories | $17.83 | 2023 | Proclaim |
| Merck Sharp & Dohme LLC | $17.76 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $17.75 | 2023 | Xarelto |
| Echosens North America, INC. | $16.66 | 2025 | Fibroscan |
| Corcept Therapeutics | $16.61 | 2024 | Korlym |
| Kowa Pharmaceuticals America, INC. | $15.87 | 2023 | Livalo, Seglentis |
| Nevro Corp. | $15.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.87 | 2023 | Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.18 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.